TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2683758
Drug: Anti-Tac monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-Tac monoclonal antibody (20 mg, administered intravenously daily for 10 days)
Study: 2683758
Drug: Anti-Tac monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-Tac monoclonal antibody
Study: 1089438
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of phenol into the lumbar sympathetic chain
Study: 1089438
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anaesthetic subcutaneously (Control)
Study: 31177752
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 3 g/day for 6 months
Study: 31177752
Drug: Perilla oil
Normalized name: Perilla frutescens leaf oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perilla oil (PO) 3 g/day for 6 months
Study: 31177752
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil mixed with linseed oil (FLO) 3 g/day for 6 months
Study: 28486976
Drug: Thromboprophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylaxis with low-molecular-weight heparin (LMWH) at a dose of 85 IU/kg once daily during asparaginase courses of ALL treatment
Study: 28486976
Drug: No thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thromboprophylaxis (standard of care) during asparaginase courses of ALL treatment
Study: 25439084
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + usual treatment
Study: 22097092
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg kg(‐1))
Study: 22097092
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 microg kg(‐1))
Study: 19857084
Drug: GoChi (Lycium
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoChi (Lycium barbarum fruit juice) at 120 mL/day for 30 days
Study: 9519518
Drug: Information leaflet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information leaflet (in patients treated with antibiotics)
Study: 9519518
Drug: No leaflet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No leaflet (control, in patients treated with antibiotics)
Study: 8287585
Drug: Naloxone (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2.4 mg)
Study: 8287585
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (1 ml)
Study: 3816314
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol via inhalation aids (InspirEase, Aerochamber, Aerosol Bag)
Study: 3816314
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol via MDI mouthpiece
Study: 3816314
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via inhalation aids
Study: 26767384
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (0.5 mg as eye drops for 10 days)
Study: 23886739
Drug: 66 mg/mL
Normalized name: pectin 66 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 66 mg/mL iodine
Study: 23886739
Drug: 100 mg/mL
Normalized name: urea 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL iodine
Study: 23886739
Drug: >133 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: >133 mg/mL iodine
Study: 20433339
Drug: Traditional dysarthria
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysarthria therapy (TRAD)
Study: 18458698
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg/kg followed by 250 µg/(kg·min)
Study: 10443336
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk supplement (1 litre daily for 4 weeks)
Study: 8527268
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg orally with grapefruit juice
Study: 8527268
Drug: Nifedipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 2.5 mg intravenously with grapefruit juice
Study: 2104736
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg orally
Study: 8527268
Drug: Nifedipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 2.5 mg intravenously
Study: 340305
Drug: Clomipramine (Anafranil)
Normalized name: clomipramine Oral Capsule [Anafranil]
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (Anafranil) plus behaviour therapy
Study: 340305
Drug: Clomipramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine plus simulated behaviour therapy
Study: 7621388
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy alone
Study: 25245625
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for 4 weeks
Study: 25245625
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for 8 weeks
Study: 19130489
Drug: 20-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-week treatment trial
Study: 11004136
Drug: Individualized dietary
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dietary counseling aiming for fat intake of 30% to 35% of daily energy, saturated/monounsaturated/polyunsaturated fatty acid ratio of 1:1:1, cholesterol intake of <200 mg/d
Study: 1519481
Drug: Interferon-alpha (IFN‐alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day for 28 days (open trial)
Study: 1519481
Drug: Interferon-alpha (IFN‐alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day (randomized trial)
Study: 1519481
Drug: Interferon-alpha (IFN‐alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN‐alpha) at doses of 3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day (randomized trial)
Study: 29691233
Drug: 50 μmol
Normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μmol oral BSE‐SFN daily for 28 days
Study: 29691233
Drug: 100 μmol
Normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μmol oral BSE‐SFN daily for 28 days
Study: 29691233
Drug: 200 μmol
Normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μmol oral BSE‐SFN daily for 28 days
Study: 24744162
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 6 months (control group)
Study: 24744162
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 18 months (study group)
Study: 22172982
Drug: Concurrent visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent visual task during text composition
Study: 20451668
Drug: Continuation phase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation phase cognitive therapy (C-CT)
Study: 2491361
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg once daily
Study: 2614884
Drug: ONO‐3708 (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐3708 (thromboxane A2 antagonist)
Study: 18615332
Drug: Betahistine 16
Normalized name: betahistine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 16 mg tid
Study: 18615332
Drug: Betahistine 24
Normalized name: betahistine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 24 mg bid
Study: 17989709
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without stem cell transplant
Study: 15950639
Drug: Single-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose (SD) protocol for GnRH antagonist (cetrorelix)
Study: 15950639
Drug: Multiple-dose (MD)
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose (MD) protocol for GnRH antagonist (cetrorelix)
Study: 15950639
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (LP) for GnRH agonist (buserelin)
Study: 7579007
Drug: epalrestat (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: epalrestat (150 mg/day, 50 mg tid, po)
Study: 7579007
Drug: placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (9 mg/day, 3 mg tid, po)
Study: 7806684
Drug: Haloperidol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (all doses)
Study: 27884499
Drug: Closed chain
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed chain exercises (CC)
Study: 19679384
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) recipe (Panax, 520 mg; Astragalus membranaceous Bunge, 520 mg; Masnetitum, 840 mg; Ostrea gigas Thumb, 470 mg; Thinleaf Milkwort Root Radix Polygalae, 450 mg; Os Draconis, 470 mg) administered as a diet supplement for 60 days.
Study: 17565930
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment administered twice daily for 5 days every 4 weeks
Study: 8985764
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mupirocin treatment)
Study: 14614669
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment
Study: 9670693
Drug: Acupuncture treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatments in addition to standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Study: 9670693
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Study: 2929157
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (chemo and radiotherapy)
Study: 26948366
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with procarbazine, lomustine, vincristine (PCV)
Study: 26948366
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with temozolomide
Study: 26948366
Drug: Delaying radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delaying radiotherapy and treatment with chemotherapy only
Study: 25422394
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three interventions
Study: 11934715
Drug: 0.05 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 ml/kg of 10 mM GSNO
Study: 10656476
Drug: Self-administered food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered food frequency questionnaire (FFQ) reviewed by a nutritionist
Study: 10656476
Drug: Self-administered food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered food frequency questionnaire (FFQ) without nutritionist review
Study: 2328304
Drug: Sublingual dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual dimenhydrinate (50 mg)
Study: 2328304
Drug: Oral dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dimenhydrinate (50 mg)
Study: 2328304
Drug: Intravenous dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dimenhydrinate (50 mg)
Study: 31158718
Drug: MI+CBT (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI+CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Study: 31158718
Drug: SC+CBT (Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC+CBT (Supportive Counselling + Cognitive Behavioral Therapy)
Study: 29420200
Drug: Anifrolumab 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab 1,000 mg
Study: 26210606
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of alcohol (.6 g/kg)
Study: 20937602
Drug: Intraperitoneal carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal carboplatin in combination with intravenous weekly dose-dense paclitaxel
Study: 20937602
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel
Study: 19448846
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for 16 weeks
Study: 17146730
Drug: Indibulin 20
Normalized name: Indibulin
DrugBank: Indibulin (DB06169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indibulin 20 mg (fed condition)
Study: 17146730
Drug: Indibulin 20
Normalized name: Indibulin
DrugBank: Indibulin (DB06169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indibulin 20 mg (fasted condition)
Study: 17146730
Drug: Indibulin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indibulin (dose escalation study)
Study: 17146730
Drug: Indibulin 60
Normalized name: Indibulin
DrugBank: Indibulin (DB06169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indibulin 60 mg (recommended dose level)
Study: 11354519
Drug: 17-beta-estradiol (E2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol (E2) administration (100 microg.d(‐1) x 3.5d -> 200 microg.d(‐1) x 3.5 d -> 300 microg.d(‐1) x 4.0 d)
Study: 11354519
Drug: 17-beta-estradiol (E2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-beta-estradiol (E2) administration
Study: 10958250
Drug: Clomipramine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (oral doses of 10-40 mg/day)
Study: 8291818
Drug: Practice guideline
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice guideline recommendation with concurrent reminders
Study: 8291818
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no concurrent reminders)
Study: 29739677
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g soy protein with 66 mg isoflavone (SPI)
Study: 29739677
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g soy protein alone (SP)
Study: 24304002
Drug: rFIXFc (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered weekly (50 IU/kg)
Study: 24304002
Drug: rFIXFc (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered every 10 days (100 IU/kg)
Study: 24304002
Drug: rFIXFc (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) administered as needed for bleeding episodes (20 to 100 IU/kg)
Study: 24304002
Drug: rFIXFc (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFIXFc (recombinant factor IX Fc fusion protein) for perioperative treatment
Study: 17980878
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test before IVF cycle
Study: 17228986
Drug: Uncertainty management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncertainty management intervention delivered during 4 weekly telephone sessions using audiotaped cognitive-behavioral strategies and a self-help manual.
Study: 10632652
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (OAC)
Study: 10632652
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg b.d.), clarithromycin (500 mg b.d.), amoxycillin (1 g b.d.) for 10 days (RAC)
Study: 3310827
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg levonorgestrel plus 0.030 mg ethinyloestradiol
Study: 3310827
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg desogestrel plus 0.030 mg ethinyloestradiol
Study: 27042166
Drug: Thermogenic fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermogenic fat loss supplement (TFLS)
Study: 20679593
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 75% expectation of receiving active medication
Study: 20679593
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 25%, 50%, or 100% expectation of receiving active medication
Study: 20679593
Drug: Prior medication
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior medication response
Study: 3280999
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy for 12 months (Group A)
Study: 3280999
Drug: Infant stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant stimulation for 6 months followed by physical therapy for 6 months (Group B)
Study: 29331971
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (control)
Study: 31501052
Drug: Inhaled POL6014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled POL6014 (doses 80 to 320 mg in subjects with CF)
Study: 31501052
Drug: Inhaled POL6014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled POL6014 (doses 20 to 960 mg in healthy volunteers)
Study: 21958742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of symptoms
Study: 21958742
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of β-blocker use
Study: 20002087
Drug: Low-dose ritonavir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ritonavir (three oral doses of 100 mg over 24 h)
Study: 20002087
Drug: ALT-2074 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALT-2074 (three oral doses of 80 mg over 24 h)
Study: 17284131
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75-225 mg/day)
Study: 15113944
Drug: Test fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test fat F (5 g/100 g long chain (n‐3) fatty acids)
Study: 12575603
Drug: Liandai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liandai Capsule
Study: 9563534
Drug: Glutamine supplements
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplements (30 g/day)
Study: 7889887
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg boron/day supplement
Study: 18394829
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day oral dehydroepiandrosterone (DHEA)
Study: 18394829
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg transdermal estradiol plus 100 mg/day oral micronized progesterone (HRT)
Study: 7624736
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g n‐3 PUFAs daily for 6 weeks
Study: 7624736
Drug: 0.65 g
Normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g n‐3 PUFAs daily for 6 weeks
Study: 2612495
Drug: Lamotrigine (Lamictal)
Normalized name: LAMOTRIGINE (LAMICTAL) 25MG TAB
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (Lamictal) as add-on therapy
Study: 944387
Drug: levodopa with
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa with L-tryptophan
Study: 29093159
Drug: CNTO6785 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO6785 15, 50, 100, or 200 mg every 4 weeks + MTX
Study: 22505632
Drug: Minocycline (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (7 days of intravenous administration)
Study: 20518927
Drug: MOD cavity
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD cavity preparation (G2)
Study: 20518927
Drug: MOD +
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MOD + root canal treatment (G3)